You are here

Article info

Article menu

Download PDFPDF

Hypothesis
Rethinking the immunotherapy numbers game

Authors

  • Rebecca A Bekker Department of Integrated Mathematical Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USACancer Biology Ph.D. Program, University of South Florida, Tampa, Florida, USA PubMed articlesGoogle scholar articles
  • Mohammad U Zahid Department of Integrated Mathematical Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA PubMed articlesGoogle scholar articles
  • Jennifer M Binning Department of Molecular Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA PubMed articlesGoogle scholar articles
  • Bryan Q Spring Translational Biophotonics Cluster, Northeastern University, Boston, Massachusetts, USADepartment of Physics, Northeastern University, Boston, Massachusetts, USADepartment of Bioengineering, Northeastern University, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Patrick Hwu Moffitt Cancer Center, Tampa, Florida, USA PubMed articlesGoogle scholar articles
  • Shari Pilon-Thomas Department of Immunology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA PubMed articlesGoogle scholar articles
  • Heiko Enderling Department of Integrated Mathematical Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USADepartment of Radiation Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Heiko Enderling; heiko.enderling{at}moffitt.org
View Full Text

Citation

Bekker RA, Zahid MU, Binning JM, et al
Rethinking the immunotherapy numbers game
Journal for ImmunoTherapy of Cancer 2022;10:e005107. doi: 10.1136/jitc-2022-005107

Publication history

  • Accepted June 21, 2022
  • First published July 6, 2022.
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.